Real-world evidence from users of a behavioral digital therapeutic for chronic insomnia

被引:27
作者
Ritterband, Lee M. [1 ,4 ]
Thorndike, Frances P. [2 ]
Morin, Charles M. [3 ]
Gerwien, Robert [2 ]
Enman, Nicole M. [2 ]
Xiong, Ray [2 ]
Luderer, Hilary F. [2 ]
Edington, Samantha [2 ]
Braun, Stephen [2 ]
Maricich, Yuri A. [2 ]
机构
[1] Univ Virginia, Ctr Behav Hlth & Technol, Dept Psychiat & Neurobehav Sci, Sch Med, Charlottesville, VA USA
[2] Pear Therapeut Inc, Boston, MA USA
[3] Univ Laval, Dept Psychol, Quebec City, PQ, Canada
[4] Univ Virginia, Ctr Behav Hlth & Technol, Dept Psychiat & Neurobehav Sci, Sch Med, POB 801075, Charlottesville, VA 22908 USA
关键词
CBT-I; Cognitive behavioral therapy for insomnia; SHUTi; Sleep healthy using the internet; Chronic insomnia; Prescription digital therapeutic; PDT; Somryst; RANDOMIZED CONTROLLED-TRIAL; CLINICAL-PRACTICE GUIDELINE; AMERICAN ACADEMY; SEVERITY INDEX; ADULTS; METAANALYSIS; EFFICACY; INTERVENTION; ASSOCIATION; MANAGEMENT;
D O I
10.1016/j.brat.2022.104084
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Background: There have been many research trials of various digital therapeutics, but few real world evaluations of their efficacy. This type of data, however, can provide a more rounded understanding of their impact, utility, reach, and adoption. Findings presented here focus on outcome and patient engagement data of SHUTi (Sleep Health Using the Internet), a digital therapeutic delivering Cognitive Behavioral Therapy for insomnia (CBT-I), in a large real-world dataset of adults with insomnia. Methods: 7216 adults who purchased access to SHUTi between December 2015 and February 2019 are included in the analysis. The Insomnia Severity Index (ISI) was administered at the beginning of each of six treatment Cores of the intervention. Users entered sleep diaries between Cores to track changes in sleep over time and obtain tailored sleep recommendations. Number of Cores completed and sleep diaries entered indicate program usage. Results: Users showed a reduction in mean ISI scores and a corresponding increase in effect size at the start of each subsequent Core (compared to Core 1) (range: d = 0.3-1.9). Effect sizes at the last Core relative to the first were moderate-to-large for diary-derived sleep onset latency and wake after sleep onset. A reduction in number of medicated nights was also found, with those with severe insomnia showing the largest reduction from last-to first week of treatment (d = 0.3). At the last Core, 61% met criteria for meaningful treatment response (reduction of > 7 points on ISI) and 40% met criteria for remission (ISI < 8). Engagement was comparable to SHUTi research trials. Conclusion: Consistent with controlled trials, real-world data suggest that digital therapeutics can result in relatively high levels of engagement and clinically meaningful sleep improvements.
引用
收藏
页数:9
相关论文
共 50 条
[21]   Real-world evidence couples genomic biomarkers with therapeutic outcomes for canine hemangiosarcoma [J].
Rodrigues, Lucas ;
Wu, Kevin ;
Harvey, Garrett ;
Post, Gerald ;
Miller, Aubrey ;
Hull, Abigail ;
Lambert, Lindsay ;
Lopes, Christina ;
Zou, James .
SCIENTIFIC REPORTS, 2025, 15 (01)
[22]   Reality check: Real-world evidence to support therapeutic development in hematologic malignancies [J].
Derman, Benjamin A. ;
Belli, Andrew J. ;
Battiwalla, Minoo ;
Hamadani, Mehdi ;
Kansagra, Ankit ;
Lazarus, Hillard M. ;
Wang, Ching-Kun .
BLOOD REVIEWS, 2022, 53
[23]   Therapeutic drug monitoring of imatinib in paediatric chronic myeloid leukaemia: Data from a real-world setting [J].
Suttorp, Meinolf ;
Sembill, Stephanie ;
Lensker, Phyllis ;
Hildebrand, Verena ;
Schirmer, Elke ;
Karow, Axel ;
Krumbholz, Manuela ;
Rauh, Manfred ;
Metzler, Markus .
BRITISH JOURNAL OF HAEMATOLOGY, 2025, 206 (05) :1397-1405
[24]   Real-world evidence of allergen immunotherapy [J].
Buta, Federica ;
Paoletti, Giovanni ;
Bragato, Maria Chiara ;
Giovannini, Mattia ;
Canonica, Giorgio Walter ;
Heffler, Enrico .
CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY, 2024, 24 (06) :529-535
[25]   Clinical feasibility of cognitive behavioural therapy for insomnia in a real-world mixed sample at a specialized psychiatric outpatient clinic [J].
Cassel, Maria ;
Blom, Kerstin ;
Gatzacis, Jannis ;
Renblad, Peter ;
Kaldo, Viktor ;
Jernelov, Susanna .
BMC PSYCHIATRY, 2022, 22 (01)
[26]   Evaluating Glycemic Control in Patients of South Asian Origin With Type 2 Diabetes Using a Digital Therapeutic Platform: Analysis of Real-World Data [J].
Krishnakumar, Arjun ;
Verma, Ritika ;
Chawla, Rajeev ;
Sosale, Aravind ;
Saboo, Banshi ;
Joshi, Shilpa ;
Shaikh, Maaz ;
Shah, Abhishek ;
Kolwankar, Siddhesh ;
Mattoo, Vinod .
JOURNAL OF MEDICAL INTERNET RESEARCH, 2021, 23 (03)
[27]   Comparing eptinezumab with onabotulinumtoxinA in the treatment of chronic migraine: a real-world evidence study [J].
Scuteri, Damiana ;
Pagliaro, Martina ;
Iannacchero, Rosario ;
Trimboli, Michele ;
Lawrence, Gary W. ;
Bagetta, Giacinto ;
Corasaniti, Maria Tiziana .
JOURNAL OF HEADACHE AND PAIN, 2025, 26 (01)
[28]   Erenumab in chronic migraine: Experience from a UK tertiary centre and comparison with other real-world evidence [J].
Khalil, Modar ;
Moreno-Ajona, David ;
Villar-Martinez, Maria Dolores ;
Greenwood, Fiona ;
Hoffmann, Jan ;
Goadsby, Peter J. .
EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 (08) :2473-2480
[29]   CGRP Targeting Therapy for Chronic Migraine-Evidence from Clinical Trials and Real-world Studies [J].
Wang, Yen-Feng ;
Wang, Shuu-Jiun .
CURRENT PAIN AND HEADACHE REPORTS, 2022, 26 (07) :543-554
[30]   Tofacitinib for Treatment of Alopecia Areata: Real-world Evidence and Factors Associated with Therapeutic Response [J].
Sanchez-Diaz, Manuel ;
Diaz-Calvillo, Pablo ;
Rodriguez-Pozo, Juan-Angel ;
Tercedor-Sanchez, Jesus ;
Cantudo-Cuenca, Maria-Rosa ;
Molina-Leyva, Alejandro ;
Arias-Santiago, Salvador .
ACTA DERMATO-VENEREOLOGICA, 2022, 102